Replies

Here is the remainder, minus the chart that is unreadable on my phone even after zooming:

Tanikawa et al examined the effect of nattokinase on the Spike protein of SARS-CoV-2. In the first experiment they demonstrated that Spike was degraded in a time and dose dependent manner in a cell lysate preparation that could be analogous to a vaccine recipient. The second experiment demonstrated that nattokinase degraded the Spike protein in SARS-CoV-2 infected cells. This reproduced a similar study done by Oba and colleagues in 2021.
Nattokinase is dosed in fibrinolytic units (FU) per gram and can vary according to purity. Kurosawa and colleagues have shown in humans that after a single oral dose of 2000 FU D-dimer concentrations at 6, and 8 hours, and blood fibrin/fibrinogen degradation products at 4 hours after administration elevated significantly (p < 0.05, respectively). Thus an empiric starting dose could be 2000 FU twice a day. Full pharmacokinetic and pharmacodynamic studies have not been completed, but several years of market use as an over-the-counter supplement suggests nattokinase is safe with the main caveat being excessive bleeding and cautions with concurrent antiplatelet and anticoagulant drugs.
Based on these findings, nattokinase and similar products such as serrapeptase should undergo well-funded, accelerated preclinical and clinical development programs. The issue at hand is the urgency of time, similar to that with SARS-CoV-2 infection and empiric early therapy. It will take up to 20 years to have a fully developed pharmaceutical profile to characterize the safety and efficacy of nattokinase in the treatment of vaccine injury and post-COVID syndromes. Large number of people are sick now and many believe empiric treatment is justified given sufficiently low risk of side effects and potentially high reward. My recommendation is to discuss this with your doctor or seek a specialist in holistic or naturopathic medicine who is experienced with the safety profile of nattokinase in a range of applications.

Here is a chatGPT summary:

The article discusses the issue of how to remove the SARS-CoV-2 spike protein from the body after vaccination. The author notes that the mRNA and adenoviral DNA products used in COVID-19 vaccines were rolled out without a clear understanding of how or when the body would break down the genetic code. The synthetic mRNA carried on lipid nanoparticles appears to be resistant to breakdown by human ribonucleases by design so the product would be long-lasting and produce the protein product of interest for a considerable time period. This would be an advantage for a normal human protein being replaced in a rare genetic deficiency state (e.g. alpha galactosidase in Fabry’s disease). However, it is a big problem when the protein is the pathogenic SARS-CoV-2 Spike. The adenoviral DNA (Janssen) should be broken down by deoxyribonuclease, however, this has not been exhaustively studied.

The accumulation of the Spike protein in cells, tissues, and organs is believed to be the driver of vaccine injury syndromes. The article suggests that dissolution of Spike protein should be a therapeutic goal for the vaccine injured. The author recommends the use of nattokinase and related peptides as a potential solution. Nattokinase is an enzyme produced by fermenting soybeans with bacteria Bacillus subtilis var. natto and has been available as an oral supplement. It degrades fibrinogen, factor VII, cytokines, and factor VIII and has been studied for its cardiovascular benefits.

The article cites a study by Tanikawa et al. that examined the effect of nattokinase on the Spike protein of SARS-CoV-2. The study demonstrated that nattokinase degraded the Spike protein in a time and dose-dependent manner in a cell lysate preparation that could be analogous to a vaccine recipient. The study also showed that nattokinase degraded the Spike protein in SARS-CoV-2 infected cells. The article suggests an empiric starting dose of 2000 fibrinolytic units (FU) twice a day for nattokinase. While full pharmacokinetic and pharmacodynamic studies have not been completed, several years of market use as an over-the-counter supplement suggests that nattokinase is safe, with the main caveat being excessive bleeding and cautions with concurrent antiplatelet and anticoagulant drugs.

The author calls for well-funded, accelerated preclinical and clinical development programs for nattokinase and similar products such as serrapeptase. However, the urgency of time, similar to that with SARS-CoV-2 infection, calls for empiric early therapy. While it may take up to 20 years to have a fully developed pharmaceutical profile to characterize the safety and efficacy of nattokinase in the treatment of vaccine injury and post-COVID syndromes, many people are sick now, and some believe empiric treatment is justified given sufficiently low risk of side effects and potentially high reward. The article recommends discussing the use of nattokinase with a doctor or seeking a specialist in holistic or naturopathic medicine who is experienced with the safety profile of nattokinase in a range of applications.